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To test the validity of the common hypothesis that 
patients with psoriasis have an inherently lower suscep-
tibility to cancer, we prospectively studied 1367 patients 
with severe psoriasis who enrolled in a clinical trial of 
oral methoxsalen photochemotherapy for treatment of 
psoriasis for an average of 3.2 yr. The incidence of non-
cutaneous cancers and the number of deaths from such 
cancers were slightly but not significantly higher than 
that expected for the general population (relative risk 
= 1.1; standard mortality ratio = 1.3). Among 318 pa-
tients (23%) in this cohort who were over 35 yr of age 
and who lacked appreciable exposure to suspected cu-
taneous carcinogens, the observed incidence for cuta-
neous carcinoma was 1.4 times that expected, based on 
rates for the general population (90% confidence interval 
= .8 to 2.7). These data suggest that patients with pso-
r iasis have a risk of systemic and cutaneous cancer that 
is comparable to the risk for the general population. 
Several genetically determined diseases t hat exhibit a de fi-
c ien cy in the repair of damaged DNA a re accompa nied by a 
higher ris k of malignancy [1,2]. S uch diseases include ataxia-
tela ngiectasia, xeroderma pigm entosum, a nd Fanconi's a nemia . 
Som e investigators believe that genetically determined differ-
e n ces in the activity of enzym es that conver t relatively inactive 
e nvironmental carcinogens to more carcinogenic metabolites 
may also increase t he risk of d eveloping cancer [3]; this risk, 
however , is less well established . In pruticular, a higher level of 
t he mixed-function oxidase, aryl hydrocarbon h ydroxylase 
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(AHH), or its inducibili ty, has been proposed as a risk factor 
for a variety of tumors [ 4,5]. 
In spite of their exposure to poten t ial cru·cinogens during 
treatm en t of t h eir disease, patients with psoriasis a1·e commonly 
believed to be at lower risk for developing cutaneous a nd 
perhaps noncutaneous carcinomas [6). R ecent experiments 
have suggested that patients with psoriasis have lower AHH 
activity in both affected a nd una ffected skin a nd other tissues, 
including liver a nd bowel [7-9]. The investigators postulated 
that, as a r esult of lower AHH activity, patients with psoriasis 
m etabolize car cinoge ns at a lower rate a nd th erefore ru·e at 
lower risk for cu taneous a nd perhaps certain noncu taneous 
cancers [9,10]. If correct, t h is hypoth esis would provide a sci-
en t ific rationale for t he long held belief that psoriatic patients 
have a lower cancer risk. 
Assessing t h e validity of t h e hypothesis t hat pat ien ts with 
psoriasis have a substan t ially lower cancer risk is important in 
t he m anagem en t of a patient's psorias is, as well as in t he 
interpretation of adverse even ts in a population being treated 
for psoriasis. If clinicia ns believe that patients wit h psoriasis 
have an inhere nt ly different risk of cancer, t heir decisivns a bout 
treatment m ay be influenced, and iatrogenic effects may be 
assessed incorrectly or may go unnoticed. 
In this communication , we present data on death rates a nd 
the incidence of cutaneous a nd noncutaneous cancer in 1367 
patien ts with psoriasis who were followed for an average of 3 
yr. Our data indicate t hat patients with psoriasis do not have a 
substan tially lower risk of developing can cer t ha n the general 
population. 
METHODS 
Since 1976, a 16-center prospective study has been evaluating the 
efficacy and toxicity of oral methoxsalen photochemotherapy (PUV A) 
used in the treatment of psoriasis. Among other findings, this study has 
documented deaths and the incidence of cutaneous and noncutaneous 
carcinomas in 1380 patients with severe psoriasis who enrolled in this 
fo llow-up study. Study methods and population characteristics have 
been detailed elsewhere [11]. 
After an average of 3.2 yr, 1,367 of the 1,380 patients (99%) had been 
interviewed directly, or a relative or close friend had been contacted to 
ascertain if the patient was still living. Of living patients, 97% were 
contacted directly. At the beginning of the study, the mean age for 
patients was 44, and patients had had psoriasis for an average of 20 yr. 
Noncutaneous Cancers 
For this investigation, we calculated the number of expected cause-
specific deaths, based on age- and sex-specific rates by pnmary reason 
for death in the United States population (12]. T he expected mc1dence 
of systemic cancer was calculated on the basis of data fl_-om the 
Connecticut Tumor Registry [1 3], which was used because of 1ts accu-
racy and wide use in studies of th is type. We then calculated the 
standard morta li ty ratios, or the ratio of observed to expected events, 
with confidence in tervals determined by Miettinen's method (1 4]. 
Cutaneous Cancers 
Our population had been exposed to substantial quanti t!es_ of a 
variety of possible cutaneous carcinogens. The apparent assoc1atwn of 
an increased risk of cutaneous carcinoma with an increasing number of 
treatments with PUV A or ionizing radiation and with a very high 
number of t reatments with conventional ul traviolet light has been 
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previously documented [11,15]. To limit the effect of these agents on 
the observed rate of cutaneous cancer, we separately studied members 
of our cohort who were 35 yr of age or older at the study's midpoint, 
who had not been previously exposed to ionizing radiation, who lacked 
high exposure to tar and conventional artificial UV light, and who had 
received fewer than 100 PUV A treatments. For this "low-exposure" 
cohort, which was followed prospectively for an average of 4.0 yr, we 
calculated the expected incidence of nonmelanoma skin cancer , based 
on age-, sex-, and geographically-specific incidence rates for the white 
population in the United States [16]. 
RESULTS 
Noncutaneous Cancers 
In 3.2 yr, 50 of 1,367 patients (4%) had died; cause of death 
was unavailable for only one. Observed deaths (38 men and 12 
women) in our population were virtually identical to those 
expected on the basis of United States rates for an age- and 
sex-matched population (39 men and 10 women) followed for 
this period of time (standard mortality rate=l.04; 90% confi-
dence interval, 0.8 to 1.4) (Table 1). (None of our patients died 
because of cutaneous cancer.) The findings summarized in 
Tables I and II indicate that neither death rates nor the 
incidence of systemic cancer, including lung and digestive tract 
malignancies, were substantially different for our population 
than would be expected on the basis of rates for the general 
population. As Table I shows, we can be 95% confident that the 
rate of death from cancer among patients with psoriasis is at 
least 70% of the rate for the general population. As Table II 
shows, we can be 95% confident that the incidence of noncuta-
neous cancer for patients with psoriasis is at least 80% of the 
rate for the general population. Our best estimate, the relative 
rate, is that the incidence of noncutaneous cancer for patients 
with psoriasis is slightly higher (by 10%) than that for the 
general population. 
Cutaneou,s Cancers 
After an average of 4.0 yr of prospective study, 9 of the 318 
patients in our low-exposure cohort developed basal cell carci-
nomas, 2 had squamous cell carcinomas, and one had both. The 
TABLE I. Observed and expected deaths, by cause, in 1,367 psoriatic 
patients followed for an average of 3.2 yr · 
Cause of death" Observed Expected SMR" 90% CI' Deaths Deaths 
Cancer 
Lung 5 3.4 1.5 0.6-3.6 
GI 5 3.1 1.6 0.5-4.9 
Other cancer 5 4.8 1.0 0.9-1.3 
Total cancer 15 11.3 1.3 0.7-2.4 
Circulatory-respiratory 25 23.7 1.1 0.8-1.4 
Accidents 4 2.3 1.7 0.6-5.3 
Other noncancerd 6 10.9 0.6 0.2-1.5 
Total deaths" 50 48.2 1.0 0.8-1.4 
"Based on Death Certificate or physician statement. 
1
' Standard Mortality Ratio. 
c Mantel-Haenszel Chi-square. 
"Includes 1 unspecific cause of death. 
TABLE II. Cancer incidence by type and sex: observed and expected 
Type of cancer Obs. Exp. RR" · 90% CI'' 
Bronchus and lung 5 3.8 1.3 0.7-2.5 
Digestive 6 6.1 1.0 
Breast 3 2.0 1.5 
Other cancers 11 10.8 1.0 
Sex 
Male 
Female 
Total-all cancers 
17 
8 
25 
" Relative Risk. 
"Mantel-Haenszel Chi-square. 
15.7 
7.0 
22.7 
1.1 
1.1 
1.1 
0.3-6.7 
0.9-1.2 
0.8-1.6 
0.5-2.7 
0.8-1.6 
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relative rate of developing cutaneous cancer in the low-exposure 
cohort was 1.4 times the rate expected, on the basis of age-, sex-
and geographically-specific rates (90% confidence interval, 0.8 
to 2.7). 
DISCUSSION 
Our data contradict the long held and recently reiterated 
hypothesis that patients with psoriasis are at lower risk for the 
development of cutaneous or noncutaneous cancer [6,9,10]. The 
death rates, proportional mortality rates, and incidence of non-
cutaneous cancer for our population closely approximated those 
expected for the general population. In fact, our patients had a 
small but not statistically significant increase in mortality and 
incidence of noncutaneous cancer. The higher incidence could 
be due to a closer surveillance of our population or a possible 
greater exposure to carcinogens as a result of their psoriasis 
treatment. In addition, our patients had the expected incidence 
of gastrointestinal malignancies, even though one study has 
reported low AHH activity in this organ system in patients with 
psoriasis [7]. 
In the 2 yr prior to initiation of PUV A, our study group 
reported an incidence of cutaneous carcinoma that was not 
significantly different than that expected for age-, sex-, and 
geographically-matched population [11]. In 4 yr of prospective 
study, 12 patients in the low-exposure cohort developed one or 
more skin tumors, compared to the 8.6 expected-a small but 
not statistically significant increase. Patients with basal cell 
carcinoma outnumbered those with squamous cell carcinoma 
by more than three to one-a ratio similar to that seen in the 
general population. Thus, our data indicate that the overall risk 
and type of cutaneous carcinoma in those patients who did not 
r~cord large exposures to cutaneous carcinogens was not very 
different than the risk in persons without psoriasis. 
Based on our data, we feel that patients with psoriasis do not 
have a ~ubsta?tially lower risk than the general population for 
developmg skm or other environmentally-related cancers. Even 
if AHH activity i~ ~o_wer in patients with psoriasis-a hypothesis 
that has been cnticiZed recently [17]-it does not seem, as one 
group has suggested [7], that the resultant difference in metab-
olism of carcinogens by this pathway substantially lowers the 
can~er risk in these pat_ients. We believe that when a physician 
decides to use potential carcinogens to treat patients with 
severe psoriasis, it would be prudent to assume that their risk 
of ~ancer i_s equal_ to_ the risk for patients without psoriasis. 
Patients with psonasis who are treated with possible carcino-
gens, i~cluding ultraviolet light, PUV A, ionizing radiation, tar 
~ystem1c ch~motherapy, and arsenic, should be carefully mon-
Itored for signs of cancers that may be associated with such 
treatments. 
We are indebted to Drs. Howard L. Bleich and Kenneth Kraemer 
for advice and to Mary Jean Moore for editorial assistance. 
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